Pharmaceutical Technology on MSN
Reunion Neuroscience expands Series A to $133m after positive trial milestones
The funding round was boosted by $30m after Reunion’s lead candidate RE104 hit efficacy goals in a Phase II trial.
Emily Standley Allard on MSN
Psychedelic Therapy: From Taboo to Mainstream Healthcare
Once relegated to the fringes of society and labeled as countercultural, psychedelics are now experiencing a renaissance—this time within the walls of mainstream healthcare. Psychedelic therapy, ...
Paul McCartney and John Lennon 's relationship was pulled back together during the Sgt. Pepper sessions through their shared ...
A new study suggests that lysergic acid diethylamide (LSD), also known as acid, could reduce anxiety. This marks the first-ever trial to evaluate the safety and efficacy of MM120 (a pharmaceutical ...
LSD reduced symptoms of anxiety in a midstage study published Thursday, paving the way for additional testing and possible medical approval of a psychedelic drug that has been banned in the U.S. for ...
Sept. 4 (UPI) --A study of a pharmaceutical form of the psychedelic drug lysergic acid diethylamide suggests it might relieve anxiety symptoms for up to three months. The results of a preliminary ...
WASHINGTON – LSD reduced symptoms of anxiety in a midstage study published Thursday, paving the way for additional testing and possible medical approval of a psychedelic drug that has been banned in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results